Sichuan Biokin Pharmaceutical Co., Ltd. Class ASSE: 688506

"SICHUAN BIOKIN PHARMACEUTICAL CO., LTD."Announcement on Voluntary Disclosure of Interim Analysis of Phase III Clinical Trial of Izalontamab Brengitecan (BL-B01D1/iza-bren) for Locally Advanced, Recurrent or Metastatic HR+HER2- Breast Cancer Achieving Primary Endpoint

· Issued by Sichuan Biokin Pharmaceutical Co., Ltd. Class A via Shanghai Stock Exchange
Announcement on Voluntary Disclosure of Interim Analysis of Phase III Clinical Trial of Izalontamab Brengitecan (BL-B01D1/iza-bren) for Locally Advanced, Recurrent or Metastatic HR+HER2- Breast Cancer Achieving Primary Endpoint

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Company analysis